背景:心力衰竭是一种慢性和进行性疾病,其中心肌无法泵送足够的血液和氧气来满足身体的需要。氧化应激和炎症是心力衰竭发展和进展的关键因素。虾青素,类胡萝卜素,具有很强的抗炎和抗氧化作用,可以保护心血管系统。一项研究将评估虾青素补充剂对炎症状态的影响,氧化应激,血脂谱,尿酸水平,内皮功能,生活质量,和心力衰竭患者的疾病症状。
方法:本研究是一项为期8周的双盲对照随机临床试验,其中心力衰竭患者被随机分为两组:干预(每天1粒含有20毫克虾青素的胶囊,n=40)和安慰剂(每天含20毫克麦芽糖糊精的胶囊,n=40)将被分割。在干预的开始和结束时,尿酸,血脂谱,氧化应激指数,炎症标志物,血压,一氧化氮,人体测量因素将被测量,和测量生活质量的问卷,疲劳强度,呼吸急促,食欲就完成了.采用SPSS22版软件进行统计分析。
结论:全球对天然和功能性食品越来越感兴趣。这项RCT有助于扩大对虾青素在心力衰竭患者中的潜在益处的研究,包括它的抗氧化剂,降脂,和抗炎作用。
背景:伊朗临床试验注册IRCT20200429047235N3。2024年3月26日注册。
BACKGROUND: Heart failure is a chronic and progressive disease where the heart muscle is unable to pump enough blood and oxygen to meet the body\'s needs. Oxidative stress and inflammation are key elements in the development and progression of heart failure.
Astaxanthin, a carotenoid, has strong anti-inflammatory and antioxidant effects that may protect the cardiovascular system. A study will evaluate the effect of
astaxanthin supplementation on inflammatory status, oxidative stress, lipid profile, uric acid levels, endothelial function, quality of life, and disease symptoms in people with heart failure.
METHODS: The current study is a double-blind controlled randomized clinical trial for 8 weeks, in which people with heart failure were randomly assigned to two groups: intervention (one capsule containing 20 mg of
astaxanthin per day, n = 40) and placebo (one capsule containing 20 mg of maltodextrin per day, n = 40) will be divided. At the beginning and end of the intervention, uric acid, lipid profile, oxidative stress indices, inflammatory markers, blood pressure, nitric oxide, and anthropometric factors will be measured, and questionnaires measuring quality of life, fatigue intensity, shortness of breath, and appetite will be completed. SPSS version 22 software will be used for statistical analysis.
CONCLUSIONS: There is a growing global interest in natural and functional food products. This RCT contributes to the expanding body of research on the potential benefits of
astaxanthin in heart failure patients, including its antioxidant, lipid-lowering, and anti-inflammatory effects.
BACKGROUND: Iranian Registry of Clinical Trials IRCT20200429047235N3. Registered on 26 March 2024.